SHAPING THE FUTURE OF CELL BIOLOGY, BIOMEDICINE AND DRUG DEVELOPMENT
Living tissues are composed of a heterogeneous population of individual cells, which can differ dramatically from each other. These differences can have important consequences for the health and propagation of the entire population. To better study disease and aid in drug development, an in-depth analysis of cell behavior and physiological responses can best be accomplished with single-cell data.
Fluicell strives to become a leading solution provider in life-science and personalized medicine. The company is a world leader and pioneer in open-volume microfluidics for the life sciences, and holds a strong IP and patent position with five different patent families in the estate. By zooming into the level of individual cells, we redefine the approach to cell biology and drug development by providing unique microfluidic technology. Our products enable access to the level of individual cells, by improving experimental abilities for localized compound delivery, ion channel screening and bioprinting.
The BioPen® is the first single-cell lab-on-a-tip tool for the life sciences sector and is used by leading universities and national health laboratories globally. It is a unique drug delivery system for targeting individual cells in vitro without contaminating the surrounding environment.
The Dynaflow® Resolve system is considered by many to be the best secondary ion channel screening platform on the market. Launched in 2004, the Dynaflow platform is an established product with global big pharma and biotech companies as customers.
As a further development of Fluicell’s existing product portfolio, the company is developing a unique high-resolution bioprinting technology in both 2D and 3D under the name Biopixlar®. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled.
We are truly excited to be part of the technology transformation in medicine and biology towards smarter, more efficient, less resource-consuming, and environmentally friendly new experimental and drug screening practices that also minimizes the use of experimental animals.
Fluicell is a public company founded in 2012, and is based in Gothenburg, Sweden.